Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Journal of Neuro-oncology
Morris D GrovesV A Levin

Abstract

Since anaplastic gliomas (AG) depend on matrix metalloproteinases for tumor cell invasion and angiogenesis, we undertook this phase II study to evaluate the matrix metalloproteinase inhibitor marimastat (MT), combined with the alkylator temozolomide (TMZ) in patients with recurrent AG, looking for improved outcomes. Patients were treated every 28 days with TMZ at 150-200 mg/m2 once daily on days 1-5 and MT at 25 mg twice daily on days 8-28. Results were compared to our database of anaplastic glioma patients treated at recurrence. A subanalysis of the relationship between MT-induced joint-related toxicity and anticonvulsant status was carried out. Forty-nine patients were enrolled; all were assessable for toxicity, and 46 were included in the efficacy analysis. Joint and muscle complaints occurred in 32 patients (65%); 1 patient was removed from the study due to toxicity. The best protocol response was a complete response in 1 patient and a partial response in 2 patients (3/46=7%, 95% confidence interval (CI)=1, 18). Median time to progression was 24 weeks (95% CI=16, 56), and the progression-free survival (PFS) rate was 48% at 6 months (95% CI=35%, 65%), which surpassed the protocol objective of 40%. Sub-analysis showed a posit...Continue Reading

References

Dec 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P D Brown, R Giavazzi
Jul 17, 1996·International Journal of Cancer. Journal International Du Cancer·A GieseM E Berens
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T WongW K Yung
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K YungV A Levin
Aug 10, 2000·Neoplasia : an International Journal for Oncology Research·M E Berens, A Giese
Nov 28, 2000·Expert Opinion on Investigational Drugs·W P Steward, A L Thomas
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Morris D GrovesVictor A Levin
Mar 20, 2002·Current Neurology and Neuroscience Reports·A J BolteusG J Pilkington
Mar 30, 2002·Science·Lisa M CoussensLynn M Matrisian
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A GieseM Westphal
Jan 31, 2004·Current Oncology Reports·Nithya Ramnath, Patrick J Creaven
Sep 7, 2004·The International Journal of Developmental Biology·Alicia R FolguerasCarlos López-Otín

❮ Previous
Next ❯

Citations

Sep 1, 2007·Anti-cancer Drugs·Riccardo SoffiettiElisa Trevisan
May 12, 2007·Expert Review of Anticancer Therapy·Marta Penas-Prado, Mark R Gilbert
Apr 7, 2009·Expert Review of Neurotherapeutics·Jan DrappatzPatrick Y Wen
May 10, 2013·Expert Review of Clinical Pharmacology·Jordi BrunaRoser Velasco
Oct 31, 2008·ANZ Journal of Surgery·Lie S ChanChristopher Christophi
Feb 13, 2009·Current Medical Research and Opinion·Renato V La Rocca, H Maximilian Mehdorn
Jun 26, 2008·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Fleur HuangDavid Roberge
Mar 24, 2017·Brain : a Journal of Neurology·Candice C PoonJohn J P Kelly
Jul 28, 2016·Platelets·Daniela Dreymueller, Andreas Ludwig
Dec 1, 2006·Expert Review of Anticancer Therapy·Lijo Simpson, Evanthia Galanis
May 7, 2011·Journal of Neuro-oncology·Michelle A RudekStuart A Grossman
Jun 15, 2019·Cellular and Molecular Life Sciences : CMLS·Venkat Raghavan KrishnaswamyIrit Sagi
Jun 22, 2016·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Ralf G RempeBjörn Bauer
Nov 18, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohan S NandhuMariano S Viapiano
Jun 16, 2010·Pharmacology & Therapeutics·Leopold ArkoJohn K Park
Aug 17, 2010·Neuroimaging Clinics of North America·Ingeborg Fischer, Kenneth Aldape

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.